Agenda
19-21 October 2026
RAI Convention Centre, Amsterdam
Amsterdam, 19 - 21 October 2026
Schedule
Create your personal agenda –check the favourite icon
Oct 1910:00
Conference pass
BioNTech’s Oncology Pipeline: Combining mRNA Cancer Immunotherapies with Next-Gen Immunomodulators and Targeted Therapies
Cancer & Therapeutic Vaccines
Oct 1910:00
Conference pass
End-to-End Cold Chain Management: Data-Driven Sustainable Vaccine Delivery
Vaccine Supply & Logistics
Giovanna Riggall, Head of Heath Supply Chain, Unimed
Chirstopher Green, Professor and Consultant Physician in Infectious Diseases & Global Health, University of Birmingham
Oct 1910:00
Conference pass
Workshop Leader
Vaccine Supply & Logistics
Chirstopher Green, Professor and Consultant Physician in Infectious Diseases & Global Health, University of Birmingham
Oct 1910:00
Conference pass
Workshop Leader
Cancer & Therapeutic Vaccines
Oct 1910:00
Conference pass
Workshop Leader’s Opening Remarks
Platform Technologies
Jeffrey Almond, Former VP Discovery R&D, Sanofi & Visiting Professor, University of Oxford
Oct 1910:15
Conference pass
A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious & Non-Communicable Diseases
Platform Technologies
Wian de Jongh, CEO, adaptvac
Oct 1910:15
Conference pass
Cross-reactive cellular immunity and molecular mimicry in cancer
Cancer & Therapeutic Vaccines
Oct 1910:30
Conference pass
From Forest to Finished GMP: Securing QS-21 for TB at Scale
Vaccine Supply & Logistics
Damian Hiley, Managing Director, Vaccine Division, Desert King
Session led by: 
Oct 1910:30
Conference pass
Novel OMV platform for mucosal vaccines
Platform Technologies
Session led by: 
Oct 1910:30
Conference pass
Standardized Serology: A Critical Foundation for HPV Vaccine Development and Implementation
Cancer & Therapeutic Vaccines
Oct 1910:45
Conference pass
Advancing Equitable Vaccine Access to Low & Middle Income Countries
Vaccine Supply & Logistics
Session led by: 
ALN Reddy, Sr Vice President, Biological E Limited
Oct 1910:45
Conference pass
Discovery of viral vector based cancer vaccine
Cancer & Therapeutic Vaccines
Session led by: 
Yong Zu, Business Development, Genevoyager Co. Ltd.
Oct 1910:45
Conference pass
Rational Design, Formulation and Process Optimization for Next-Gen mRNA-LNP Vaccines and Therapeutics
Platform Technologies
Oct 1911:00
Conference pass
From API to Patient: Building an End-to-End Vaccine Supply Chain for Global Impact - TBC
Vaccine Supply & Logistics
Session led by: 
Oct 1911:00
Conference pass
Revolutionizing MVA – single dose and continuous cell-line manufacturing
Platform Technologies
Senthil Ranganathan, VP, Technical Development and CMC Operations, GeoVax Labs, Inc.
Session led by: 
Oct 1911:00
Conference pass
Update on myNEO-Powered Cancer Vaccine Programs: First-in-Class Antigen Discovery for Personalized and Off-the-Shelf Dark-Antigen Vaccines
Cancer & Therapeutic Vaccines
Oct 1911:15
Conference pass
AI designed universal vaccine technology to prevent future virus outbreaks
Platform Technologies
Oct 1911:15
Conference pass
Closing the Gap: Vaccine Integrity Through the Last Mile
Vaccine Supply & Logistics
Oct 1911:15
Conference pass
Enabling Safe and Effective Cancer Immunotherapy: through Alithea’s liquid biopsy and AI Platforms
Cancer & Therapeutic Vaccines
Session led by: 
Oct 1911:30
Conference pass
Immunity Takes Care of Your Skin: The Vaccine Reinventing Acne Treatment
Cancer & Therapeutic Vaccines
Oct 1911:30
Conference pass
Vaccine development using recombinant Vesicular Stomatitis Virus (VSV) as platform technology
Platform Technologies
Arianna Marini, Associate Director, Global Clinical Immunology, IAVI
Oct 1911:45
Conference pass
Recombinant shingles vaccine linked to lower risk of dementia and cardiovascular events: natural experiments
Cancer & Therapeutic Vaccines
Maxime Taquet, Associate Professor, University of Oxford
Oct 1912:00
Conference pass
Panel: Modelling Supply Chain Resilience: From Digital Twins to Global Strategy
Vaccine Supply & Logistics
- What does a true “digital twin” of a vaccine supply chain look like, beyond simple forecasting models?
- How can digital twins help predict and prevent bottlenecks across manufacturing, fill-finish, and distribution?
- What data is essential to buildan accurate, end-to-end digital replica of the vaccine supply chain?
- How can simulation outputs translate into real procurement, inventory, and allocation decisions?
- Where are the current gaps between modelling insight and operational action?
Gemma Lahuerta, Parenteral Development Director, LABORATORIO REIG JOFRE, S.A.
Niall Macaulay, Policy Officer, Health Emergency Preparedness and Response Authority
Heiko Keller, Supply Chain Manager, Center for Pandemic Vaccines and Therapeutics (ZEPAI) at Paul-Ehrlich-Institute (PEI)
Oct 1912:00
Conference pass
Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts
Cancer & Therapeutic Vaccines
Oct 1912:00
Conference pass
Some considerations on the utility of vaccination platforms, old and new
Platform Technologies
Oct 1912:15
Conference pass
Panel: Building Next-Generation Vaccine Platforms: Innovation, Stability, and Scalability
Platform Technologies
Arianna Marini, Associate Director, Global Clinical Immunology, IAVI
Moderator: Jonathan Hare, Translational Science Lead, The Francis Crick Institute
Oct 1912:15
Conference pass
Panel: Chronic Conditions and Off-target Effects of Vaccines
Cancer & Therapeutic Vaccines
- What evidence exists for vaccines (BCG, MMR, Shingles) affecting unrelated infections or chronic conditions like asthma, allergy, or dementia?
- Are current trial designs sufficient to capture long-term, non-specific outcomes?What guidance can regulators offer to standardize "trained immunity" endpoints in early-phase trials?
- Canpathogen-agnosticvaccine benefits bevalidated, and how do we engage regulators and industry?
Moderator: Robbert Van der Most, CEO, Vaxxcellence
Nicholas Perombelon, Head of Vaccines and Therapies, EMA
Gregory Glenn, CEO, Total Trials (formerly known as FHI Clinical)
Oct 1914:00
Conference pass
Reducing Zero-Dose Vaccinations in Africa: Digital Strategies and Continental Initiatives
Vaccine Safety & Access
Fidele Ngabo Gaga, Head of RMNCAH Division, Africa CDC
Oct 1914:00
Conference pass
Workshop Leader
Vaccine Safety & Access
Walter Straus, Vice President, Clinical Safety & Risk Management, Moderna Therapeutics
Oct 1914:00
Conference pass
Oct 1914:00
Conference pass
Workshop Leader’s Opening Remarks
Vaccine Delivery
David Burkhart, CEO, Inimmune Corp
Oct 1914:15
Conference pass
Global market landscape of vaccine manufacturing and procurement for improved access
Vaccine Safety & Access
Georgios Stathopoulos, Technical Officer, Vaccine Access, World Health Organization
Oct 1914:15
Conference pass
Panel: From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery
Vaccine Delivery
Are you intrigued by new delivery technologies,but you are reluctant to adopt in your program because you currently assume:
- Needles are good enough
- there is not enough real-world evidence to support its efficacy
- the regulatory pathway will be difficult
- the delivery technology is not compatible with your therapy
- patient adoption will be difficult
- it is too risky or costly to integrate the technology into your pipeline
Come and learn why these assumptions are mostlyoutdated, and why now,more than ever, severalnew technologies may provide you with the advantage you need for enhanced efficacy and patient adoption of your therapeuticor vaccine product.
Session led by: 
Marco Cavaleri, Head of Public Health Threats, European Medicines Agency
Oct 1914:15
Conference pass
Panel: Preparing for Disease X: Approaches for the Next Spillover
Biothreats & Disease X
- How can human, animal, and environmental health systems work together to detect and reduce zoonotic spillover risks at their source?
- What lessons fromrecentspillovers (e.g.Hantavirus,Bundibugyo virus,Avian influenza) should inform future surveillance, vaccine development, and response strategies?
- How can governments, researchers, and industry strengthen cross-sector collaboration before and during the next Disease X event?
- What role should vaccines play in proactive prevention, rapid platform deployment, and stockpiling?
Nicola Lewis, Director of Worldwide Influenza Centre, The Francis Crick Institute
Ab Osterhaus, Director of Research Center For Emerging Infections and Zoonoses and Professor, University of Veterinary Medicine Hannover
Meghan Pennini, Director, Translational Science, Foundation for the National Institutes of Health
Jerome Kim, Director General, IVI
Oct 1914:30
Conference pass
Systems Biology to Define Actionable Biomarkers of Vaccine Safety
Vaccine Safety & Access
Oct 1914:45
Conference pass
Assessing and Monitoring Vaccine Safety in the AI Era
Vaccine Safety & Access
Oct 1915:00
Conference pass
Innoture's coated Microarray Patch platform for vaccines
Vaccine Delivery
Oct 1915:00
Conference pass
Panel: Global Vaccine Access: Balancing Speed and Safety
Vaccine Safety & Access
- Where do reliance and expedited pathways genuinely speed access without compromising safety?
- What has worked, and what has broken down, in real regulatory submissions?
- How do we move from pilots and one-off successes to predictable, trusted pathways?
Ana Milinkovic, Global Regulatory Lead, GSK
Nicholas Perombelon, Head of Vaccines and Therapies, EMA
Dakshina Reddy, Head of Global Regulatory Strategy and Operations, Bill & Melinda Gates Medical Research Institute
Moderator: Walter Straus, Vice President, Clinical Safety & Risk Management, Moderna Therapeutics
Oct 1915:15
Conference pass
Moderna’s Clinical Development of Bundibugyo Ebolavirus Vaccine
Biothreats & Disease X
Oct 1915:15
Conference pass
Novel Oral Protease Inhibitor Adjuvants Encapsulated in Nano- and Microparticles to Enhance Mucosal Vaccination
Vaccine Delivery
Oct 1915:30
Conference pass
Pandemic flu: mRNA H5 vaccine
Biothreats & Disease X
Oct 1915:30
Conference pass
Redefining Vaccination: Delivering the Future Through High-Density Microarray Patches
Vaccine Delivery
Thomas Lake, Chief Business Officer+, Vaxxas
Oct 1915:45
Conference pass
Gavi, the Vaccine Alliance: Driving Global Vaccine Access and Market Shaping
Vaccine Safety & Access
Maria Verykiou, Policy Manager, Gavi, the Vaccine Alliance
Oct 1915:45
Conference pass
Polio Eradication: A Challenge for Vaccine Delivery
Vaccine Delivery
Session led by: 
Marta Murreddu, Business Development Director, Cerba Research
Oct 1915:45
Conference pass
Title TBC
Biothreats & Disease X
Simon Nyovuura Antara, Director, African Field Epidemiology Network (AFENET)
Session led by: 
Oct 1916:00
Conference pass
Current State of European Health Information Integrity. Readout by the European Infodemiology Initiative
Vaccine Safety & Access
Europe’s health information environment is increasingly cross-border, fast-moving, and consequential for vaccine confidence and uptake. Drawing on the European Infodemiology Initiative’s engagement with European institutions, national health authorities, public health associations, and healthcare professional networks, this presentation will provide a readout on current activities to strengthen health information integrity across Europe.The presentation will also offer a general assessment of how the field is developing, including areas of progress, persistent operational challenges, and priorities requiring greater coordination and investment. Attendees will gain a concise overview of Europe’s current direction and the systems being built to support more timely, relevant, and coordinated vaccine communication
Joe Smyser, Chief Executive Officer, PGP (The Public Good Projects)
Oct 1916:00
Conference pass
Strengthening Scientific Advice for Pandemic Decision-Making: Insights from Interdisciplinary Simulation Exercises
Biothreats & Disease X
Oct 1916:15
Conference pass
Digitally Enabled Vaccine Delivery in Wales
Vaccine Delivery
Wales built its national vaccination platform one campaign at a time. The Welsh Immunisation System began as a pandemic response and grew, increment by increment, into the system that now delivers the winter respiratory programmes (COVID-19, RSV and flu) across all seven health boards, with more than 13 million vaccinations recorded.
This talk follows what that platform makes possible once it sits on common data standards and a shared record from stock to surveillance. Because every dose is recorded once, in structured and FHIR-compliant form, and shared through the system. The same data supports high-quality effectiveness and safety studies. WIS data contributed to the four-nation UK study of RSV vaccine effectiveness published in The Lancet Regional Health (Europe) in 2026, which found adjusted effectiveness against hospitalisation of 82% in Wales. The same record also lifts uptake: it identifies who is eligible, prioritises by clinical risk, prompts invitations and reminders, and shows where coverage is falling short by deprivation in near real time.
Wales is now extending the platform to school-age immunisation, beginning with MenB in late summer 2026, on the way to delivering every vaccine, end to end, within one digital solution. The session is for anyone working at the implementation end of the value chain, and it sets out where the opportunities lie for manufacturers, funders and researchers who need delivery and real-world evidence at national scale.
Oct 1916:15
Conference pass
Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence
Biothreats & Disease X
- How do we integrate genomics, clinical data, and modelling into one trusted decision-making framework?
- What data must be shared globally, what should remainlocal, and where does coordination still fail?
- How can early warning systems inform vaccine strainselectionand manufacturing?
- How cantools like wastewater surveillance, digital health records, and community reporting detect outbreaks before hospitals feel the impact?
- Where do delays occur between data generation and policy action, and how do we shorten that gap?
Ankur Mutreja, Director of External Affairs and Health Security, South Asia-PATH
Swati Gupta, Former VP of Head of Emerging Infectious Diseases and Epidemiology, IAVI, Fulcrum Health
Oct 1916:15
Conference pass
Panel: Vaccine Acceptance: Safety, Communication and Access
Vaccine Safety & Access
- How do we communicate rare adverse events with context and proportionality?
- When recommendations change, how do we explain why without damaging confidence?
- What are the distinct roles ofregulators, government, manufacturersand clinicians invaccinecommunication?
- What are the main system-level barriers to vaccine uptake?
Elissa R Weitzman, Associate Professor, Director of Research, Boston Children's Hospital, and Harvard Medical School
Sibilia Quilici, Executive Director, Vaccines Europe
Moderator: Joe Smyser, Chief Executive Officer, PGP (The Public Good Projects)
Oct 1916:30
Conference pass
Novel combination vaccines against endemic pathogens for children under 5 years old.
Vaccine Delivery
Farzana Muhib, Asia Team Lead, Vaccine Implementation, PATH
Oct 1916:45
Conference pass
Novel approaches to measure the value of combination vaccines
Vaccine Delivery
Create your personal agenda –check the favourite icon
Oct 209:00
Conference pass
The Technology Revolution: Agility for the Wave of Next Generation Vaccines
Keynotes
- What new vaccines are on the horizon and what are our key scientific leaders championing?
- How close are we to precision immunology?What is the roadmap for platform vaccines in oncology, autoimmune disorders, and infectious diseases?
- What are the key performance and logistical benefits of advanced platforms(e.g. RNA)compared to traditional vaccine approaches?
- Which platformtechnologies are most likely to cut response timelines and deliver on the 100-day mission?
- How are regulatory agencies adapting their approval pathways to novel vaccines, new antigens andusing AI in vaccine R&Dandmanufacturing?
Marco Cavaleri, Head of Public Health Threats, European Medicines Agency
Jerome Kim, Director General, IVI
Lucy Chappell, Chief Scientific Adviser, UK Department of Health and Social Care
Annaliesa Anderson, SVP & Chief Vaccines Officer, Pfizer
Track 1
Oct 2010:15
Conference pass
One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime
Keynotes
- How can combination vaccines support life-course immunisation strategies and close immunity gaps at every age?
- Could combining priority pathogens in a single shot improve vaccine coverage, or will it introduce new barriers for uptake and delivery?
- What isthe economic value of combination vaccines?
- What standards do we need to ensure multi-antigen vaccines perform consistently without compromising safety or effectiveness?
- What strategies can we use to ensure broad accessibility of combination vaccines, including considerations around technology, adjuvants, and formulation?
- Which pairings have the strongest potential to reduce global disease burden, especially in regions with limited resources?
Nicola Rose, Interim Executive Director of Science and Research, MHRA
Mark Jit, Chair and Professor, Department of Global and Environmental Health, New York University
Birgitte Giersing, Team Lead, Vaccine Prioritization, World Health Organisation (WHO)
Track 1
Oct 2011:30
Conference pass
Working Group: Forging Outbreak-ready Vaccine Partnerships
Working Groups
Track 6
Oct 2011:30
Conference pass
Working Group: Title TBC
Working Groups
Kevin Mugenyi, Senior Epidemiologist, African Field Epidemiology Network (AFENET)
Saheed Oluwatoyin Gidado, National Coordinator, NSTOP Nigeria, African Field Epidemiology Network (AFENET)
Session led by:
Patrick Mboya Nguku, Regional Coordinator Anglophone West, AFENET
Track 5
Oct 2011:30
Conference pass
Working Group: Vectored Vaccine Platforms: from design to improving efficacy
Working Groups
Session led by: Tonix Pharmaceuticals
Sina Bavari, Executive Vice President, Infectious Disease Research and Development, Tonix
Gabriella Worwa, Study Director, Tonix Pharmaceuticals
Track 5
Oct 2012:40
Conference pass
Start-up Pitch 1: ImmuneSpec
Startup Pitches
Elisa Rosati Scalchi, Scientific Lead, ImmuneSpec BV
EXPO
Oct 2012:40
Conference pass
Start-up Pitch 1: ImmuneSpec
Startup Pitches
Elisa Rosati Scalchi, Scientific Lead, ImmuneSpec BV
Expo Stage
Oct 2012:45
Conference pass
Start-up Pitch 2: IDEVAX
Startup Pitches
Vanessa Vankerckhoven, CEO & Founder, IDEVAX
Expo Stage
Oct 2012:50
Conference pass
Start-up Pitch 3: PhagePro
Startup Pitches
Minmin Yen, CEO & Co-Founder, PhagePro, P.B.C.
Expo Stage
Oct 2014:00
Conference pass
Architects of immunity: Future vaccines using state-of-the-art adjuvant - TBC
Formulation & Bioprocess
Session led by: 
Dennis Christensen, Head of Global R&D, Croda Inc
Track 2
Oct 2014:00
Conference pass
H5N1 Preparedness: A CRO’s Strategic Response to Emerging Threats - TBC
COVID & Beyond
Session led by: 
Track 5
Oct 2014:00
Conference pass
HIV vaccine design in nonhuman primates
Pre-Clinical Development
Richard Wyatt, Director Viral Immunology, IAVI Center for Neutralizing Antibodies, The Scripps Research Institute
Track 6
Oct 2014:00
Conference pass
Learnings from CD4 T-cell immune profiling: how the past determines the future
Immune Profiling
Robbert Van der Most, CEO, Vaxxcellence
Track 4
Oct 2014:00
Conference pass
Pragmatic Randomised Vaccine Trials: Generating the Evidence Policymakers Need
Clinical Trials
Track 3
Oct 2014:00
Conference pass
Track Chair
Clinical Trials
Track 3
Oct 2014:00
Conference pass
Oct 2014:00
Conference pass
Track Chair
Pre-Clinical Development
Track 6
Oct 2014:00
Conference pass
Track Chair
Immune Profiling
Robbert Van der Most, CEO, Vaxxcellence
Track 4
Oct 2014:00
Conference pass
Oct 2014:00
Conference pass
Vibro®Membrane Filtration (VMF) - Novel Technology for MF/UF Applications
Technology Showcases
Session led by: 
Track 1
Oct 2014:15
Conference pass
Beyond Binding: Broad Fc Effector Function Profiling to Accelerate Vaccine and Immunotherapy Development
Immune Profiling
Lenny Moise, VP, Research, SeromYx
Session led by: 
Track 4
Oct 2014:15
Conference pass
Nanofiber Patches as a New Platform for Mucosal Vaccine Delivery
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:15
Conference pass
Next-Generation LNP: Advancing mRNA Vaccine Performance
Pre-Clinical Development
Track 6
Oct 2014:30
Conference pass
Accelerating Vaccine Quality Control with Next-Generation Sequencing
Technology Showcases
Session led by: 
Antoine Millet, Viral Safety and Regulatory Affairs Specialist, PathoQuest
Track 1
Oct 2014:30
Conference pass
Designing a High-Impact Clinical Development Plan: From Strategy to Execution in Vaccine Development
Clinical Trials
Session led by: 
Track 3
Oct 2014:30
Conference pass
LNP-mediated delivery for mRNA vaccines: from infectious diseases to multi-antigen cancer immunotherapy
COVID & Beyond
Session led by: 
Track 5
Oct 2014:30
Conference pass
Research and development of vaccines against Enterovirus D68
Pre-Clinical Development
Session led by: 
Track 6
Oct 2014:30
Conference pass
The Recombinant Advantage: Enhancing Virus Titer and Stability Without the Serum-Derived Risks
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:45
Conference pass
“Standardize Serology”: A cornerstone for Vaccine Licensure and Pandemic Preparedness
Clinical Trials
Session led by: 
Track 3
Oct 2014:45
Conference pass
Accelerating vaccine immune profiling with multiplexing solutions for serum and single-cell analysis
Immune Profiling
Session led by: 
Track 4
Oct 2014:45
Conference pass
Get the edge in nanomedicine formulation and characterization
Formulation & Bioprocess
Session led by: 
Track 2
Oct 2014:45
Conference pass
Virus-like particles as tools to support vaccine development
Pre-Clinical Development
Session led by: 
Track 6
Oct 2016:00
Conference pass
Beyond COVID-19 and strategies for better mRNA vaccines
COVID & Beyond
Session led by: 
Track 5
Oct 2016:00
Conference pass
Driving Vaccine Development in LMICs: Case Studies from Norovirus and Polio Trials - TBC
Clinical Trials
Session led by: Emmes Biopharma Services LLC
Track 3
Oct 2016:00
Conference pass
FORGE-AI: An immunogen design platform enabling next-generation vaccines for RSV, HMPV, PIV and influenza virus
Pre-Clinical Development
Session led by: 
Track 6
Oct 2016:00
Conference pass
Multiplexing neutralisation for priority pathogens
Immune Profiling
Track 4
Oct 2016:00
Conference pass
Panel: Expanding the Access & Impact of Adjuvants
Formulation & Bioprocess
- How can we overcome IPand licensing challenges to make novel adjuvants more globally accessible?
- How can regulators harmonize approval pathways for adjuvanted vaccines without compromising safety or slowing innovation?
- How can collaboration between academia, industry, and funders, accelerate development and equitable distribution of new adjuvants?
- What emerging adjuvant platforms or innovative technologies are available that could transform next-generation vaccines, and what obstacles exist to their deployment?
Session led by:
Dennis Christensen, Head of Global R&D, Croda Inc
Roland Ventura, Head of Strategy, Vaccine Formulation Institute
Track 2
Oct 2016:00
Conference pass
Safe and Efficacious Circular RNA Vaccines to Treat Yellow Fever and Dengue
Technology Showcases
Session led by: 
Peter Weinstein, Chief Executive officer, Circurna
Track 1
Oct 2016:00
Conference pass
Oct 2016:00
Conference pass
Oct 2016:00
Conference pass
Track Chair
Pre-Clinical Development
Track 6
Oct 2016:15
Conference pass
Eliminating the Cold Chain: A Fridge-Free Td Vaccine From Concept to Clinical Trials - TBC
Clinical Trials
Session led by: 
Karen O'Hanlon, Chief Development Officer, Stablepharma
Track 3
Oct 2016:15
Conference pass
Persistent Neurobiological Consequences of SARS-CoV-2 Infection: Multimodal Evidence from Non-Human Primate Models
COVID & Beyond
Session led by: 
Track 5
Oct 2016:15
Conference pass
Platform for Manufacturing Broad-Protecting Protein-Based Vaccines Against Fast-Evolving Viruses
Technology Showcases
Paco Pino, VP R&D, ExcellGene
Session led by: 
Track 1
Oct 2016:15
Conference pass
Oct 2016:15
Conference pass
Using AI to design antigens in pandemic preparedness
Pre-Clinical Development
Track 6
Oct 2016:30
Conference pass
Advancing COVID-19 vaccination strategies: integrating science, technology and real-world insights
COVID & Beyond
Session led by: 
Track 5
Oct 2016:30
Conference pass
Developing the next generation broad-spectrum vaccines
Clinical Trials
Tim Hirst, CEO, GPN Vaccines Ltd
Track 3
Oct 2016:30
Conference pass
Enabling tomorrow's RNA therapies - from lab to patients at scale
Technology Showcases
Session led by: 
Track 1
Oct 2016:30
Conference pass
Precision Prevention of Lung Cancer: Development of the ChAdOx2-LungVax Cancer Vaccine
Immune Profiling
Track 4
Oct 2016:30
Conference pass
Preclinical development of a West Nile virus RNA vaccine
Pre-Clinical Development
Track 6
Oct 2017:10
Conference pass
One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy
Keynotes
- How can integratedOne Healthsurveillanceguide vaccine prioritisation across humans, animals, and ecosystems?
- What joint funding models and pipeline management strategiescan acceleratehigh-risk zoonotic diseaseslike avian influenza?
- How can insights from spillover events, vector ecology, and AMR shape vaccine strategy andpandemicpreparedness?
- What cross-sector partnerships are most effective in translatingOne Healthprinciples into coordinated vaccine actionand policy?
Moderator: Keith Sumption, Former Chief Veterinary Officer, FAO
Erick Lelouche, President, LYONBIOPOLE
Track 1
Create your personal agenda –check the favourite icon
Oct 219:00
Conference pass
The New Geopolitics of Vaccines: Global Vaccine Manufacturing in a Fractured World
Keynotes
- How can public-private partnerships mitigate the risks of vaccine nationalism?
- How toensureequitableaccess to vaccines andmaintainingmanufacturing continuity across global hubs during a public health emergency?
- What innovative manufacturingtechnologies(modularmanufacturing,digital twins,etc.)canspeed upresponsesandpandemicpreparedness?
- Howcould governments and industry balance the push for domestic manufacturing sovereignty with the efficiencies and interdependencies of a globalised supply network?
Wolfgang Philipp, Principal Adviser for Health and Crisis Management, Directorate-General for Health and Food Safety (SANTE), European Comission
Skhumbuzo Ngozwana, Director of Manufacturing, Africa CDC
Track 1
Oct 2110:30
Conference pass
AMR & Bacterial Vaccines Track Chair
AMR & Bacterial Vaccines
Jan Poolman, Executive Advisor & Founder, CreaBacVac B.V.
Track 6
Oct 2110:30
Conference pass
Bioprocess & Manufacturing Track Chair: Richard Welch
Bioprocess & Manufacturing
Track 2
Oct 2110:30
Conference pass
Chair’s opening remarks
One Health & Veterinary
Jeremy Salt, Chief Executive Officer, The Vaccine Group
Track 4
Oct 2110:30
Conference pass
Chair’s opening remarks
Respiratory
Jerald Sadoff, Chief Medical Officer, Centivax
Track 5
Oct 2110:30
Conference pass
Clinical Trials Track Chair
Clinical Trials
Track 3
Oct 2110:30
Conference pass
Emerging & Infectious Diseases Track Chair
Emerging & Infectious Diseases
Track 1
Oct 2110:30
Conference pass
FinDementia - A Pragmatic phase 4 trial designed to demonstrate effectiveness of recombinant shingles vaccine against dementia
Clinical Trials
Arto A. Palmu, Chief Scientific Officer, FVR – Finnish Vaccine Research | FVR – Suomen rokotetutkimus
Track 3
Oct 2110:30
Conference pass
From crisis to preparedness: vaccine development during and between outbreaks lessons from the Bundibugyo virus (BDBV) PHEIC
Emerging & Infectious Diseases
Track 1
Oct 2110:30
Conference pass
From Innovation to Impact: Translating Next-Generation Vaccine Technologies into Clinical Reality
Bioprocess & Manufacturing
Track 2
Oct 2110:30
Conference pass
How can a microneedle manufacturer contribute to the success of cancer vaccine developers?
Biopharma Showcases
Jeffrey Stolwijk, Scientific Director, Uneedle
EXPO
Oct 2110:30
Conference pass
Results from the Phase 3 E.mbrace study: Exploring the Lack of Efficacy of a 9-Valent Vaccine (ExPEC9V) for the Prevention of Invasive Escherichia coli Disease in Older Adults
AMR & Bacterial Vaccines
Track 6
Oct 2110:40
Conference pass
Innovative targeted viral vectors delivering toxic payload in solid tumor : Demonstration of efficacy in Glioblastoma
Biopharma Showcases
EXPO
Oct 2110:45
Conference pass
Avian Flu (H5N1): Status of Livestock Vaccination Policies in the EU and Global Trade Implication
One Health & Veterinary
Sanna Mesman, Veterinary Policy Officer, European Comission
Track 4
Oct 2110:45
Conference pass
Innovative Adjuvants for Global Health
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2110:45
Conference pass
MF59-adjuvanted cell-derived higher-dose influenza vaccine: Building the Evidence for Influenza Prevention
Respiratory
Esther Heijnen, Head Development, Seqirus
Mendel Haag, Sr. Director, CSL Seqirus
Track 5
Oct 2110:45
Conference pass
Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response
Emerging & Infectious Diseases
- How do we spot outbreaks earlier in practice, not just in theory? What role do surveillance, genomics, community reporting, and data sharing really play on the ground?the critical role of medical interventions, particularly vaccines, in managing andcontainingemergingand infectious disease outbreaks.
- What role do medical countermeasures, particularly vaccines, play in recent outbreak responses (e.g.hantavirus, Bundibugyo virus, avian influenza), and how are these experiences shaping preparedness around speed, coordination, and decision-making under uncertainty?
- Where are the biggest gaps right now, funding, manufacturing readiness, regulatory pathways, or last-mile delivery, and who needs to act first?
Marcus Lacey, Exec Director Global Pandemic, CSL Seqirus
Folake Olayinka, Director of Immunisation, Africa CDC
Track 1
Oct 2110:45
Conference pass
Streamline your RSV early development program from FIH to POC CHIM
Clinical Trials
Session led by: 
Jelle Klein, Medical Director CPU, SGS Belgium NV.
Track 3
Oct 2110:50
Conference pass
Enrollment as a Leading Indicator: A Blinded Case Study in Fast-Enrolling Vaccine Trials
Biopharma Showcases
Ben Carmel, Chief Revenue Officer, Slope Clinical
EXPO
Oct 2111:00
Conference pass
Accelerating Vaccine Development: End to End Manufacturing and Innovation Platform - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2111:00
Conference pass
AI-Immunology™-Powered Development of Vaccines Against Bacterial Infections
AMR & Bacterial Vaccines
Track 6
Oct 2111:00
Conference pass
Driving Vaccines into the Clinic – Implementing a Proven Preclinical Evaluation Platform Approach
Clinical Trials
Session led by:
Track 3
Oct 2111:00
Conference pass
FluSNIFF-Toddler: Driving Innovation and Access in Primary Care Research
Biopharma Showcases
Oct 2111:00
Conference pass
Panel: Rethinking Livestock Vaccination for Emerging Threats
One Health & Veterinary
- How will investments in pandemic-prevention vaccines affect the development of vaccines for emerging zoonotic threats in livestock?
- How do regulatory systems for human and animal vaccines differ, and is it realistic to achieve similar approval speeds for both?
- How can we balance rapid vaccine deployment with food safety, ecological, and trade risks, and do the benefits of live attenuated vaccines(e.g. for ASF)outweigh potential biosafety concerns?
- How can economic incentives, such as advanced market commitments, best accelerate the development and market entry of new livestock vaccines?
Sanna Mesman, Veterinary Policy Officer, European Comission
Track 4
Oct 2111:10
Conference pass
Keeping Recruitment Moving in Vaccine Trials
Biopharma Showcases
Session led by: 
Ellery Nadarajah, Chief of Staff, Delfa
EXPO
Oct 2111:15
Conference pass
Critical Considerations in Nasal Vaccine Development: Targeted Delivery, and Biologic Compatibility
AMR & Bacterial Vaccines
Track 6
Oct 2111:15
Conference pass
Protecting Where Infection Begins: Intranasal Antibody Administration for the Prevention of Respiratory Viral Infection
Respiratory
Clarissa Koch, Chief Scientific Officer, Leyden Labs
Session led by: 
Track 5
Oct 2111:20
Conference pass
Cost-effective vaccine manufacturing at commercial scale: reducing footprint, labor, and COGS through intensified fixed-bed bioprocessing
Biopharma Showcases
EXPO
Oct 2111:30
Conference pass
AI-Immunology for the discovery and design of novel vaccine targets
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 2111:30
Conference pass
High infection rates achieved with the worlds’ first RSV B challenge model; a key component of our RSV-hMPV-PIV combination vaccine efficacy testing platform – TBC
Respiratory
Session led by: 
Alex Mann, Senior Director Clinical Science, Hvivo
Track 5
Oct 2111:30
Conference pass
Phase III Study of an Intranasal Quadrivalent Inactivated Whole Virion Influenza Vaccine in Healthy Japanese Participants Aged 13–64 Years
Clinical Trials
Session led by:
Track 3
Oct 2111:30
Conference pass
Redefining Nanocarrier Manufacturing with Scalable Continuous scCO₂ Processing for Advanced Vaccine Delivery
Biopharma Showcases
Session led by: 
Oct 2111:30
Conference pass
The development and manufacturing of Human Viral Challenge Agents (HVCA), a safe GMP solution for accelerating vaccine development - tbc
Bioprocess & Manufacturing
Session led by: 
Ysaline Roland, Head of Bioprocess Department, NAOBIOS
Track 2
Oct 2112:00
Conference pass
Working Group: Quality Communication for Vaccine Literacy and Uptake
Working Groups
Vaccine confidence remains one of the most important determinants of successful immunization programs globally. As new vaccines are introduced and recommendations evolve, the need for clear, consistent, and trusted communication becomes increasingly important.
This working group provides a unique opportunity to bring together experts with complementary perspectives to identify approaches that improve vaccine literacy and foster trust. The goal is to move beyond discussion and develop practical recommendations that organizations can use to communicate more effectively, engage communities, and support informed vaccination decisions.
The session aligns with broader efforts to strengthen public confidence in vaccines, improve health literacy, and ensure that evidence-based information remains accessible and actionable for the audiences who need it most.
Kashmira Date, Medical, Pfizer
Nicholas Perombelon, Head of Vaccines and Therapies, EMA
Track 5
Oct 2112:00
Conference pass
Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used?
Working Groups
Farzana Muhib, Asia Team Lead, Vaccine Implementation, PATH
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Laura Cornelissen, Team lead VPD - Epidemiology of Infectious Diseases, Sciensano
Birgitte Giersing, Team Lead, Vaccine Prioritization, World Health Organisation (WHO)
Track 4
Oct 2112:15
Conference pass
Execution of large vaccine clinical development programs
Clinical Trials
Julia Oswald, Senior Director Project Management, Respiratory, Infectious Diseases & Vaccines, PPD clinical Research business of Thermo Fisher Scientfic
Track 3
Oct 2112:15
Conference pass
Reducing Risk and Enabling Scalable Viral Vaccine Manufacturing Through Serum-Free Media
Bioprocess & Manufacturing
Session led by: 
Madhavsai Gajjar, Upstream Processing (USP) Field Application Scientist., Thermo Fisher
Oct 2112:15
Conference pass
The New Geography of Vaccine Innovation: Why the Next Decade of Vaccine Development Will Be Driven by LMICs
Emerging & Infectious Diseases
Session led by: Emmes Biopharma Services LLC
Track 1
Oct 2112:15
Conference pass
Title TBC
Biopharma Showcases
Basiel Cole, Project leader, Senior Scientist, Ziphius Vaccines
Session led by: 
EXPO
Oct 2112:15
Conference pass
VXV-01, a vaccine targeting Candida and healthcare-associated priority Gram-negative bacterial infections
AMR & Bacterial Vaccines
Session led by: 
Track 6
Oct 2112:45
Conference pass
Design and development of mRNA-encoded tuberculosis vaccines
AMR & Bacterial Vaccines
Track 6
Oct 2113:00
Conference pass
EV-D68 Vaccine Development
Emerging & Infectious Diseases
Session led by: 
Peter Soema, Project Manager, Intravacc
Track 1
Oct 2113:00
Conference pass
Global Manufacturing and Access Strategy for a TB Vaccine: MTBVAC
AMR & Bacterial Vaccines
Track 6
Oct 2113:10
Conference pass
Vaccine & beyond : the power of an integrated biomanufacturing ecosystem
International Bioclusters
EXPO
Oct 2113:15
Conference pass
Avian influenza viruses: how to cope with antigenic diversity for pandemic preparedness and vaccine design?
Respiratory
Rory De Vries, Associate Professor, Erasmus M.C.
Track 5
Oct 2113:15
Conference pass
Efficacy of Early Vaccination Against Avian Influenza in Commercial Poultry
One Health & Veterinary
Track 4
Oct 2113:15
Conference pass
Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance using Real-World Data from Prospective Observational Studies: a PrIMAVeRa-Ecraid partnership
AMR & Bacterial Vaccines
Elske Sieswerda, Clinical Microbiologist and Epidemiologist, Ecraid
Valentjin Schweitzer, Clinical Microbiologist and Epidemiologist, University of Utrecht
Track 6
Oct 2113:15
Conference pass
TNX-801 vaccine platform safety and efficacy
Emerging & Infectious Diseases
Session led by: Tonix Pharmaceuticals
Farooq Nasar, Director, Virology, Research and Development Center, Tonix Pharma
Gabriella Worwa, Study Director, Tonix Pharmaceuticals
Track 1
Oct 2113:15
Conference pass
Unlocking the potential of inline process analytical technology (PAT) for advanced bioprocess development, scale-up, and control
Bioprocess & Manufacturing
Katharina Dahlmann, Application and PAT Expert, Hamilton Bonaduz AG
Session led by: 
Track 2
Oct 2113:30
Conference pass
Advancing European Competitiveness: Innovation in Vaccine Manufacturing Technology through AI, ML, and Modeling
Bioprocess & Manufacturing
Track 2
Oct 2113:30
Conference pass
InFECT-Nl and the dutch public-private ecosystem
International Bioclusters
Eline Van Der Hoek, Managing Director, InFECT-NL
EXPO
Oct 2113:30
Conference pass
Panel: Controlled Human Infection Models (CHIMs): Evidence, Ethics and the Next Phase of Vaccine R&D
Clinical Trials
Faith Osier, Co-director, Imperial College London
Christine Dahlke, Translational Immunology Lead, CEPI
Track 3
Oct 2113:30
Conference pass
Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle
AMR & Bacterial Vaccines
- How to define bacterial priorities for AMR vaccine and monoclonal antibody R&D (pathogen, region, health economics).
- Role of modelling and cost-effectiveness frameworks
- Aligning funders, PDPs, and pharma around the biggest-impact targets
Mateusz Hasso-Agopsowicz, Technical Officer, World Health Organization
Ankur Mutreja, Director of External Affairs and Health Security, South Asia-PATH
Amelia Mosley, Sr. Director of R&D Partnerships, IAVI
Moderator: Irina Meln, Head of Innovation, European Vaccine Initiative
Track 6
Oct 2113:30
Conference pass
Platform leverage in vaccine development: how diversified technologies and adjuvant innovation are reshaping protection for older adults,
Respiratory
Emilie Danve-Chery, Global Project Head - Research Portfolio & Strategy Vaccines, Sanofi
Nnenna Chime, Head Global Clinical Franchise - Vaccines, Sanofi
Track 5
Oct 2113:40
Conference pass
Belgium as a Vaccine Clinical Trials Hub: Fast, Reliable Clinical Trials in a Strong Regulatory Ecosystem
International Bioclusters
- The National Competent Authorities as part of the European Medicines Regulatory Network
- National initiatives to attract vaccine clinical trials in Belgium
- Performance of Belgium for vaccine trials since the application of the Clinical Trial Regulation
Nele Steens, Head of R&D Division, FAGG
EXPO
Oct 2113:45
Conference pass
A novel strategy for a vaccine development and commercialization engine
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 2113:45
Conference pass
Next Generation vaccines to prevent cross-species transmission of Influenza
One Health & Veterinary
Joanne Marie Del Rosario, Team Leader - Antigen Payload Development, DIOSynVax Limited
Track 4
Oct 2113:45
Conference pass
Oct 2114:00
Conference pass
From mucosal immunology to nasal vaccines: a scientific journey
Respiratory
Session led by: 
Track 5
Oct 2114:00
Conference pass
The Potential of Novavax’s Technology Platform, including Matrix-M® adjuvant
Emerging & Infectious Diseases
Session led by: 
Track 1
Oct 2114:00
Conference pass
Oct 2114:10
Conference pass
From Emergency Response to Permanent Preparedness: Italy's Investment in Strategic Health Infrastructure and the European Vaccine Hub
International Bioclusters
Gianluca Polifrone, General Manager, Fondazione Biotecnopolo di Siena
EXPO
Oct 2114:15
Conference pass
From Kit to Custom: Development of an Accurate In-House Host Cell DNA and Sizing Assay - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:15
Conference pass
Genome-led vaccine target discovery for animal African trypanosomiasis
One Health & Veterinary
Track 4
Oct 2114:15
Conference pass
LukAB toxoid as a Staphylococcus aureus vaccine antigen candidate
AMR & Bacterial Vaccines
Track 6
Oct 2114:15
Conference pass
Neutralising antibody is a poor predictor of protection by candidate EBV vaccines
Emerging & Infectious Diseases
Alexander Douglas, Associate Professor, University of Oxford
Track 1
Oct 2114:15
Conference pass
New Tuberculosis Vaccines
Respiratory
Track 5
Oct 2114:15
Conference pass
Next-Generation Vaccines: Integrating VLP and VLP-cRNA Platforms for Broad-Spectrum, Durable Protection - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:15
Conference pass
Novel CHIMs for Influenza, RSV, and C. difficile: Results from INNO4VAC
Clinical Trials
Track 3
Oct 2114:30
Conference pass
First-in-Human Clinical Evaluation of a K1/K2 Glycoconjugate Vaccine Against Hypervirulent Klebsiella pneumoniae: Preliminary Safety and Functional Immunogenicity Results
Clinical Trials
Session led by: 
Oct 2114:30
Conference pass
Novel vaccines to protect against Traveler’s Diarrhoea
AMR & Bacterial Vaccines
Track 6
Oct 2114:30
Conference pass
Optimizing Downstream Processing for Next-Generation Vaccine Development - TBC
Bioprocess & Manufacturing
Session led by: 
Track 2
Oct 2114:30
Conference pass
Optimizing Downstream Processing for Next-Generation Vaccine Development - TBC
Bioprocess & Manufacturing
Session led by:
Track 2
Oct 2114:30
Conference pass
Panel: Bridging Species: Veterinary Vaccine Innovation for a Shared Health Future
One Health & Veterinary
- How can platform technologies such as mRNA and viral vectors be adapted and approved efficiently across species?
- How can modern vaccine platforms (e.g., mRNA, viral vectors) be adapted and scaled for livestock and wildlife, and approved efficiently across species? How can human vaccine sites be used to manufacture animal vaccines?
- How do we incentivise R&D for high-impact livestock and wildlife diseases with limited commercial return?
- What models ensure equitableaccess to veterinary vaccines, particularly in LMICs?
- How can veterinary vaccination reduce antimicrobial use and support AMR strategies?
Moderator: Keith Sumption, Former Chief Veterinary Officer, FAO
Catrina Stirling, Director, Regulatory Affairs, Zoetis
Ab Osterhaus, Director of Research Center For Emerging Infections and Zoonoses and Professor, University of Veterinary Medicine Hannover
Track 4
Oct 2114:30
Conference pass
Panel: Why Is TB Still Stuck? Applying Respiratory Vaccine Innovation to the Top Infectious Killer
Respiratory
- How must clinical trial design evolve to support the next generation of respiratory vaccines, and what lessons from RSV, COVID and influenza can be applied to TB to shorten timelines without compromising rigor?
- How cannewbiomarkersand digitaldiagnostics helpusidentifyhigh-risk patientsearlier and improve trial efficiency for TB and other respiratory pathogens?
- TB is often treated as a "neglected" disease. How do we shift the narrative to make TB a corerespiratoryvaccinepriority for global health security and private-sector investment?
Morten Ruhwald, Chief Medical Officer, Novo Nordisk Foundation Initiative for Vaccines and Immunity
Ole Olesen, Professor, European Vaccine Initiative
Judith Kallenberg, Senior Director, Global Health Access, GSK
Track 5
Oct 2114:30
Conference pass
Speed by Design: Building Vaccine Manufacturing Platforms for Rapid Response
Emerging & Infectious Diseases
Session led by: 
Angelo Raggioli, Head of Technology Development, ReiThera Srl
Track 1
Oct 2114:45
Conference pass
Building Clinical Data Infrastructure for Multi-Country Studies in Africa
Clinical Trials
Session led by: 
Track 3
Oct 2114:45
Conference pass
From Meningococcus to Gonococcus: A Vaccine Journey Across Two Pathogens
AMR & Bacterial Vaccines
Mariagrazia Pizza, Professor of Microbiology, Imperial College London
Track 6
Oct 2114:45
Conference pass
Update on Hookworm Vaccine Initiative
Emerging & Infectious Diseases
Track 1
Oct 2115:00
Conference pass
End to end Vaccines Manufacturing at Recipharm
Bioprocess & Manufacturing
Vaccine developers succeed when they can focus on the science, not on stitching together a fragmented manufacturing supply chain. In this talk, Luisa Amoedo Otero, VP Operations, Advanced Biologicsat Recipharm, draws on more than 22 years of GMP/GLP biomanufacturing and CDMO experience to present Recipharm's end-to-end, "bench to clinic" approach to vaccine manufacturing.
The talk traces the full development pathway within a single CDMO network, from process development through preclinical, clinical (Phase I–III), and commercial-scale production, highlighting how consolidating these stages reduces handoffs and technology transfers to accelerate time-to-clinic and time-to-market. It surveys the technological breadth underpinning this model: cell culture and downstream purification for recombinant protein vaccines;upstream/downstream optimization across mammalian, insect, and microbial systems;and capabilities spanning plasmid DNA, xRNA, lipid nanoparticles, viral vectors, sterile fillandfinish(including mRNA vaccines in lyophilised and liquid formats)and AI-enabled process analytical technology aimed at continuous, next-generation manufacturing. Fillandfinishas well asdelivery format considerations are discussed as decisions integrated early with formulation and stability planning rather than treated as a downstream afterthought.
Central to the talk is Recipharm's collaboration model: transparent, shared visibility into timelines, risk, and quality data across a coordinated network of 17sites in the EU and US, designed to give partners a consistent experience regardless of location or platform. The talk closes by situating this model within current global pressures(vaccine access in low- and middle-income countries, pandemic preparedness, and the need for speed with emerging platforms like xRNA)arguing that technology-agnostic, end-to-end manufacturing capability is a source of resilience and speed for vaccine developers today.
Session led by: 
Track 2
Oct 2115:00
Conference pass
Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling
Clinical Trials
- How can modelling bridge the interface between CMC parameters, clinical data, and trial design to better support development and regulatory decision-making?
- What evidence do regulators need to gain confidence in modelling-driven approaches, including adaptive trials and model-informed regulatory submissions?
- Can modelling meaningfully reduce trial size, timelines, or dose arms while stillmaintainingconfidence in safety and efficacy outcomes?
- How valuable are model-informed approaches during accelerated development or emergency situations, and are we overestimating what models can reliably predict from limited early-stage data?
Moderator: Andrew Deavin, Senior Director, GSK
Mats Welin, Senior Expert, Medical Products Agency Lakemedelsverket
Francois Beckers, Head Global Biostatistical Sciences, Sanofi
Olivier Collignon, Senior Biostatistician, European Medicines Agency
Track 3
Oct 2115:00
Conference pass
The world is waiting for a Klebsiella vaccine, where are we?
AMR & Bacterial Vaccines
Track 6
Oct 2115:15
Conference pass
A Phase 2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a C. difficile Adjuvanted Vaccine in Healthy Adults
AMR & Bacterial Vaccines
Juleen Gayed, Clinical Development Medical Director, Pfizer
Track 6
Oct 2115:15
Conference pass
Advances in Microneedle Array Patch Technology for Next‑Generation Vaccine Delivery
Bioprocess & Manufacturing
Session led by: 
Tim Peterson, Scientific Director, Dermal Drug Delivery, Kindeva Drug Delivery
Track 2
Oct 2115:15
Conference pass
Oct 2115:15
Conference pass
Novel surrogate whole-sporozoite vaccine candidates against Plasmodium vivax malaria
Emerging & Infectious Diseases
Track 1
Oct 2115:30
Conference pass
Extended valency pneumococcal vaccines to tackle emerging pneumococcal infection
AMR & Bacterial Vaccines
Track 6
Oct 2115:30
Conference pass
From DNA to Dose: Automated Cell-Free Systems for Decentralised Vaccine Production
Bioprocess & Manufacturing
Jonathan Jones, Manager - Microbial Fermentation, CPI
Track 2
Oct 2115:30
Conference pass
Maternal vaccine introduction in LMICs
Respiratory
Kashmira Date, Medical, Pfizer
Track 5
Oct 2115:30
Conference pass
Priority disease lists for new vaccines to reduce antimicrobial use
One Health & Veterinary
Track 4
Oct 2115:30
Conference pass
Why the highest-leverage move against AMR may not be a human vaccine at all…
One Health & Veterinary
Track 4
Oct 2116:00
Conference pass
Europe’s Vision for Global Health Security: Designing Sustainable Vaccine Financing and Preparedness Systems
Keynotes
- How can Europedefineevidence-based criteriato decidewhen eradication, elimination,or long-term control of major infectious threats(i.e.Health Threat Prioritisation Assessment formedicalcountermeasures)is achievable and desirable?
- What economic models and tools are needed to ensure predictable, long-term investment in vaccine R&D, manufacturing platforms, and preparedness infrastructureand implementation of immunisation programs?
- How can European institutions pivot global R&D and preparedness financing from reactive, crisis-driven surges to mission-oriented, multi-decade planning?
- Which policy levers, such as long-term contracts, advance market commitments, and pooled procurement, can reliably diversify andstabilize vaccine supply for both routine immunisation and emergency response?
Maarten Postma, Chair, Faculty of Economics & Business,, University of Groningen
Thomas Waite, Deputy Chief Medical Officer, Department of Health and Social Care
Moderator: Rachel Bonnifield, Director of Global Health Policy and Senior Fellow, Center for Global Development
Track 1
last published: 11/Sep/26 09:15 GMT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events